Microcrystals as DAMPs and their role in joint inflammation

Rheumatology (United Kingdom)

Volumn 51, Issue 7, 2012, Pages 1154-1160

  Busso, Nathalie ^a   So, Alexander ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Animal models; Crystal arthropathies; Cytokines; Inflammation; Physiology

Indexed keywords

ADAPTOR PROTEIN; BACTERIAL RNA; CALCIUM PHOSPHATE; CALCIUM PYROPHOSPHATE; CANAKINUMAB; CANCER GROWTH FACTOR; COLCHICINE; CRYOPYRIN; HYDROXYAPATITE; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; OVALBUMIN; OXALIC ACID; PROTEIN; PROTEIN DANGER ASSOCIATED MOLECULAR PATTERN; PROTEIN INHIBITOR; PROTEIN KINASE SYK; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; STEROID; TRIAMCINOLONE; UNCLASSIFIED DRUG; URATE;

ARTHRITIS; ATHEROSCLEROSIS; CELL COMPONENT; CELL INTERACTION; CRYSTAL; CRYSTALLIZATION; DENDRITIC CELL; GOLD STANDARD; GOUT; HUMAN; HYPERURICEMIA; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MICROSCOPY; MOUSE STRAIN; NONHUMAN; OSTEOARTHRITIS; PAIN; PHAGOCYTOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TH2 CELL;

ARTHRITIS; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INFLAMMATION MEDIATORS;

EID: 84863830197     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker524     Document Type: Review

References (47)

1. McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961;54: 452-60.
2. Chen YH, Hsieh SC, Chen WY et al. Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGFbeta1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3. Ann Rheum Dis 2011;70:1655-63.
3. Campion EW, Glynn RJ, Delabry LO. Asymptomatic hyperuricemia: risks and consequences in the normative aging study. Am J Med 1987;82:421-6.
4. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010;12:223.
5. Katz WA, Schubert M. The interaction of monosodium urate with connective tissue components. J Clin Invest 1970;49:1783-9.
6. Roddy E, Zhang W, Doherty M. Gout and nodal osteoarthritis: a case-control study. Rheumatology 2008;47: 732-3.
7. Ea HK, Nguyen C, Bazin D et al. Articular cartilage calcification in osteoarthritis: insights into crystal-induced stress. Arthritis Rheum 2011;63:10-8.
8. Fuerst M, Bertrand J, Lammers L et al. Calcification of articular cartilage in human osteoarthritis. Arthritis Rheum 2009;60:2694-703.
9. MacMullan P, McMahon G, McCarthy G. Detection of basic calcium phosphate crystals in osteoarthritis. Joint Bone Spine 2011;78:358-63.
10. McCarthy GM, Cheung HS. Point: hydroxyapatite crystal deposition is intimately involved in the pathogenesis and progression of human osteoarthritis. Curr Rheumatol Rep 2009;11:141-7.
11. Rosenthal AK. Crystals, inflammation, and osteoarthritis. Curr Opin Rheumatol 2011;23:170-3.
12. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-5.
13. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516-21.
14. Kool M, Willart MA, van Nimwegen M et al. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity 2011;34:527-40.
15. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10: 417-26.
16. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009;27: 229-65.
17. Martinon F, Petrilli V, Mayor A et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41.
18. Pazar B, Ea HK, Narayan S et al. Basic calcium phosphate crystals induce monocyte/macrophage IL-1beta secretion through the NLRP3 inflammasome in vitro. J Immunol 2011;186:2495-502.
19. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010;327: 296-300.
20. Piccini A, Carta S, Tassi S et al. ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way. Proc Natl Acad Sci USA 2008;105:8067-72.
21. Ryckman C, Gilbert C, de Medicis R et al. Monosodium urate monohydrate crystals induce the release of the proinflammatory protein S100A8/A9 from neutrophils. J Leukoc Biol 2004;76:433-40.
22. Liu-Bryan R, Scott P, Sydlaske A et al. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005;52:2936-46.
23. Chen CJ, Shi Y, Hearn A et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006; 116:2262-71.
24. Ng G, Sharma K, Ward SM et al. Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity 2008;29:807-18.
25. Popa-Nita O, Proulx S, Pare G et al. Crystal-induced neutrophil activation: XI. Implication and novel roles of classical protein kinase C. J Immunol 2009;183: 2104-14.
26. Popa-Nita O, Rollet-Labelle E, Thibault N et al. Crystal-induced neutrophil activation. IX. Syk-dependent activation of class Ia phosphatidylinositol 3-kinase. J Leukoc Biol 2007;82:763-73.
27. Collins MK, Tanigawa G, Kissonerghis AM et al. Regulation of T-cell receptor gene expression in human T-cell development. Proc Natl Acad Sci USA 1985;82: 4503-7.
28. Allen PM, Matsueda GR, Evans RJ et al. Identification of the T-cell and Ia contact residues of a T-cell antigenic epitope. Nature 1987;327:713-5.
29. Joosten LA, Ea HK, Netea MG et al. Interleukin-1beta activation during acute joint inflammation: a limited role for the NLRP3 inflammasome in vivo. Joint Bone Spine 2011; 78:107-10.
30. Guma M, Ronacher L, Liu-Bryan R et al. Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum 2009;60:3642-50.
31. Stehlik C. Multiple interleukin-1beta-converting enzymes contribute to inflammatory arthritis. Arthritis Rheum 2009; 60:3524-30.
32. Joosten LA, Netea MG, Mylona E et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 2010;62: 3237-48.
33. Narayan S, Pazar B, Ea HK et al. Octacalcium phosphate crystals induce inflammation in vivo through interleukin-1 but independent of the NLRP3 inflammasome in mice. Arthritis Rheum 2011;63: 422-33.
34. Jin C, Frayssinet P, Pelker R et al. NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy. Proc Natl Acad Sci USA 2011;108:14867-72.
35. Duewell P, Kono H, Rayner KJ et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464: 1357-61.
36. Caicedo MS, Desai R, McAllister K et al. Soluble and particulate Co-Cr-Mo alloy implant metals activate the inflammasome danger signaling pathway in human macrophages: a novel mechanism for implant debris reactivity. J Orthop Res 2009;27: 847-54.
37. Cohen S, Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol 2010;22:330-5.
38. So A, Desmedt T, Revaz S et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:R28.
39. Cho M, Ghosh P, Hans G et al. The safety and efficacy of anakinra in the treatment of acute gout in hospitalized patients. Arthritis Rheum 2010;62:163.
40. Terkeltaub R, Sundy JS, Schumacher HR et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebocontrolled, monosequence crossover, nonrandomised, single-blind pilot study. Ann Rheum Dis 2009;68:1613-7.
41. Terkeltaub R, Schumacher HR, Saag KG et al. Evaluation of rilonacept for prevention of gout flares during initiation of urate-lowering therapy: results of a phase 3, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62:152.
42. So A, De Meulemeester M, Pikhlak A et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010;62: 3064-76.
43. Schlesinger N, Mysler E, Lin HY et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a doubleblind, randomised study. Ann Rheum Dis 2011;70: 1264-71.
44. Announ N, Palmer G, Guerne PA et al. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine 2009;76: 424-6.
45. McGonagle D, Tan AL, Madden J et al. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 2008;58:631-3.
46. Chevalier X, Goupille P, Beaulieu AD et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009;61:344-52.
47. Bacconnier L, Jorgensen C, Fabre S. Erosive osteoarthritis of the hand: clinical experience with anakinra. Ann Rheum Dis 2009;68:1078-9.